Approval for the exablate model 4000 type 1. 0 system (exablate neuro). This device is indicated for use in the unilateral thalamotomy treatment of idiopathic essential tremor patients with medication-refractory tremor. Patients must be at least age 22. The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the exablate device.
Device | EXABLATE |
Classification Name | Mr-guided Focused Ultrasound System |
Generic Name | Mr-guided Focused Ultrasound System |
Applicant | InSightec |
Date Received | 2015-10-21 |
Decision Date | 2016-07-11 |
Notice Date | 2016-07-25 |
PMA | P150038 |
Supplement | S |
Product Code | POH |
Docket Number | 16M-2183 |
Advisory Committee | Neurology |
Expedited Review | No |
Combination Product | No |
Applicant Address | InSightec 5 Nahum Heth Street tirat-hacarmet 39120 |
Summary: | Summary of Safety and Effectiveness |
Labeling: | Labeling |
Post-Approval Study: | Show Report Schedule and Study Progress |
Approval Order: | Approval Order |
Supplemental Filings
Supplement Number | Date | Supplement Type |
P150038 | | Original Filing |
S024 |
2022-10-12 |
Normal 180 Day Track No User Fee |
S023 |
2022-08-05 |
Real-time Process |
S022 | | |
S021 |
2022-03-10 |
Real-time Process |
S020 |
2022-03-08 |
30-day Notice |
S019 | | |
S018 | | |
S017 | | |
S016 | | |
S015 | | |
S014 |
2021-03-31 |
Panel Track |
S013 |
2020-10-23 |
Normal 180 Day Track |
S012 |
2019-08-08 |
Normal 180 Day Track |
S011 |
2019-03-26 |
30-day Notice |
S010 | | |
S009 | | |
S008 |
2018-07-23 |
Normal 180 Day Track |
S007 |
2018-04-23 |
30-day Notice |
S006 |
2018-03-07 |
Panel Track |
S005 |
2018-02-20 |
Normal 180 Day Track |
S004 |
2017-08-16 |
Normal 180 Day Track No User Fee |
S003 |
2017-03-28 |
Normal 180 Day Track |
S002 |
2017-01-17 |
Normal 180 Day Track |
S001 |
2016-08-03 |
Normal 180 Day Track No User Fee |
NIH GUDID Devices